Skip to main content
Smart Investors Daily
IN

NASDAQ · INVO

INVO Bioscience, Inc.

Healthcare · Medical - Devices

$0.83

Down-$0.02 (-2.00%)

Updated Oct 23, 2026, 4:08 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.25M
P/E ratio
-0.03
Dividend yield
0.00%
52-week range
$0.52 – $3.50
Volume
125.26K
Avg. volume
1.18M

Price performance · INVO

INVO price history

1M range · 0 trading sessions · Daily adjusted prices

INVO does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest INVO news

The latest Smart Investors Daily articles mentioning INVO.

INVO research

Overview

Company profile and research snapshot.

Company profile

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
INVO recent ratings
DateFirmRatingTarget
Apr 13, 2022Roth CapitalNeutral—
Jan 19, 2022Maxim GroupBuy—
Aug 18, 2021Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Dec 2, 2025

INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the “Offering”). The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $1.69. The warrants will have an exercise price of $1.69 per share, will be exercisable upon shareholder approval and will expire on the five year anniversary from such date of shareholder approval.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.